Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Generic Name
- Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
用于：1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染；
2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥；
3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员；
4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少；
5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。
- Associated Conditions
- -
- Associated Therapies
- -
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 26
- Registration Number
- NCT03761914
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸St. Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸Innovative Clinical Research Institute (ICRI), Whittier, California, United States
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Paul Szabolcs
- Target Recruit Count
- 8
- Registration Number
- NCT03630211
- Locations
- 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 19
- Registration Number
- NCT03600350
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
- First Posted Date
- 2018-05-29
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Ultimovacs ASA
- Target Recruit Count
- 30
- Registration Number
- NCT03538314
- Locations
- 🇺🇸
John Wayne Cancer Center, Santa Monica, California, United States
🇺🇸St. Luke's University Health Network, Easton, Pennsylvania, United States
🇺🇸University of Iowa Carver College of Medicine, Iowa City, Iowa, United States
Sequential Therapy With WLL/Inhaling GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- Dai Huaping
- Target Recruit Count
- 60
- Registration Number
- NCT03316651
- Locations
- 🇨🇳
China Japan Friendship Hispital, Beijing, China
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- First Posted Date
- 2017-10-09
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Emory University
- Target Recruit Count
- 176
- Registration Number
- NCT03304821
- Locations
- 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
REO13 Melanoma With of Without GM-CSF
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2018-05-04
- Lead Sponsor
- University of Leeds
- Registration Number
- NCT03282188
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
- Conditions
- Interventions
- First Posted Date
- 2017-07-19
- Last Posted Date
- 2018-03-27
- Lead Sponsor
- Fujian Cancer Hospital
- Registration Number
- NCT03222089
- Locations
- 🇨🇳
Rongbo Lin, Fuzhou, Fujian, China
Study of Chemoimmunotherapy for High-Risk Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT03189706
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 59
- Registration Number
- NCT03033303
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.